## SOLV: Solventum Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.43 indicates fundamental undervaluation. Quality metrics strong (ROE 37%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-5.5% MRS), overbought RSI (79).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($81.40)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Solventum Corporation (SOLV) Stock Price | Live Quotes & Charts | NYSE**
- Source: StocksToTrade | 20251204T002223 | Neutral | Relevance: 100%
- This article provides live stock quotes and charts for Solventum Corporation (SOLV), showing its current stock price and daily change. It also presents analyst ratings, though none are available, and notes the absence of earnings information. The page includes prompts for users to discover popular stocks and sign up for trade alerts.

**2. Solventum stock rating upgraded to Buy at BTIG on improved execution By Investing.com**
- Source: Investing.com Nigeria | 20251202T122600 | Bullish | Relevance: 100%
- BTIG upgraded Solventum (NYSE:SOLV) from Neutral to Buy, setting a price target of $100.00, citing improved execution and overcoming initial challenges faster than expected for the healthcare spin-out. The upgrade reflects optimism about Solventum's top-line growth and increased margins, supported by recent divestitures and acquisitions. Despite a recent EPS miss, the company's strategic moves, including the acquisition of Acera Surgical and a share repurchase program, are expected to drive future growth and shareholder value.

**3. Solventum stock rating upgraded to Buy at BTIG on improved execution**
- Source: Investing.com | 20251202T062500 | Bullish | Relevance: 100%
- BTIG upgraded Solventum (NYSE:SOLV) from Neutral to Buy, setting a price target of $100.00, citing improved execution and a stronger outlook for 2026. This upgrade reflects the company's faster-than-expected resolution of initial challenges, debt reduction through divestiture, and consistent performance against guidance, despite a recent EPS miss. The company also announced plans to acquire Acera Surgical and a $1 billion share repurchase program.

**4. Korea Investment CORP Grows Holdings in Solventum Corporation $SOLV**
- Source: MarketBeat | 20251204T071256 | Bullish | Relevance: 100%
- Korea Investment CORP significantly increased its stake in Solventum Corporation ($SOLV) by 46.2% in Q2, acquiring 28,726 shares to hold a total of 90,933 shares valued at approximately $6.90 million. Solventum itself has authorized a $1.0 billion share repurchase program, covering up to 7.5% of its outstanding stock, and surpassed quarterly earnings expectations with $1.50 EPS on $2.10 billion revenue, setting FY2025 guidance at $5.98-$6.08 EPS. The stock holds a "Hold" consensus rating with a target price of $85.56 from MarketBeat analysts.

**5. (SOLV) Volatility Zones as Tactical Triggers**
- Source: Stock Traders Daily | 20251203T211000 | Neutral | Relevance: 100%
- This article provides a detailed AI-driven analysis for Solventum Corporation (NASDAQ: SOLV), highlighting neutral near-term readings and potentially stalling mid-term strong sentiment. It outlines three distinct institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis for support and resistance levels.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | BTIG | $100 | $0 | 0% |
| 2025-11-10 | UBS | $79 | $77 | +3% |
| 2025-11-07 | Piper Sandler | $98 | $94 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | BTIG | up | Buy |
| 2025-11-10 | UBS | main | Neutral |
| 2025-11-07 | Piper Sandler | main | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 0 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+5.3%)
- Independent Franchis: 7.4% (+27.2%)
- Blackrock Inc.: 5.9% (+6.1%)
- Trian Fund Managemen: 4.9% (0.0%)
- State Street Corpora: 3.6% (+1.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.43 suggests fair value with growth premium. Forward P/E 13.4x stretched relative to 6% growth. Quality metrics strong (ROE 37%, margin 18%). Institutional flow bullish (8 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.0B |
| Beta | 1.00 |
| 52W Range | $60.70 - $88.20 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.43 |
| Forward P/E | 13.4 |
| Current P/E | 14.2 |
| YoY Growth | 5.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 11.0% to 5.5% (-5.5% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 86th percentile. MRS_5 (-0.6%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 7.8% shows strong absolute momentum above own 20MA. Outperforming sector by 7.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.56), confirming momentum. RSI overbought at 79, risk of mean reversion. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.52% (CS: 86) | Strong |
| RSI_14 | 78.8 | Overbought |
| MACD Histogram | 0.56 | Bullish |
| vs SMA20 | 1.078x | Above |
| vs SMA50 | 1.144x | Above |
| vs SMA200 | 1.163x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $85.26
- **Stop Loss:** $81.40 (4.5% risk)
- **Target:** $92.98 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 129
- **Position Value:** $10,998.54
- **Portfolio %:** 11.00%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-26 (Est: $1.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $1.50 | +4.7% |
| 2025Q2 | $1.45 | $1.69 | +16.2% |
| 2025Q1 | $1.22 | $1.34 | +9.7% |
| 2024Q4 | $1.31 | $1.41 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*